APT

NCT00542451 📎

Regimen

Experimental
Paclitaxel 80 mg/m2 weekly x 12 plus trastuzumab weekly x 12 followed by trastuzumab to complete 1 year (single-arm).
Control
N/A (single-arm).

Population

HER2-positive node-negative early breast cancer with tumors up to 3 cm (majority T1, many <=1 cm), considered at low risk of recurrence.

Key finding

APT established weekly paclitaxel + trastuzumab (12 weeks) followed by trastuzumab to 1 year as the standard low-intensity regimen for small, node-negative HER2+ tumors. Avoids anthracycline and pertuzumab exposure with excellent long-term outcomes.

Source: PMID 25564897

Timeline

  • Publication: 2015 Jan 8

Guideline citations

  • NCCN BREAST